Date |
Symbol |
Description |
Type |
Disease |
Designation |
Success Rating |
Q2 2016
|
TNXP |
|
Phase 2 Results |
Neurology |
None |
|
H2 2017
|
MNTA |
|
Phase 2 Results |
Oncology |
Fast Track, Orphan Drug |
|
09/15/2016
|
DVAX |
|
PDUFA |
Infectious Disease |
None |
|
H2 2016
|
ADMA |
|
PDUFA |
Autoimmune |
None |
|
Q2 2016
|
RIGL |
|
Phase 3 Results |
Autoimmune |
None |
|
09/14/2016
|
ARLZ |
|
PDUFA |
Cardiovascular |
None |
|
Q3 2016
|
TNXP |
|
Phase 3 Results |
Neurology |
Special Protocol Assessment |
|
05/01/2016
|
ACAD |
|
PDUFA |
Neurology |
Breakthrough Therapy, Priority Review |
|
10/22/2016
|
MDVN |
|
PDUFA |
Oncology |
None |
|
Q4 2017
|
MRUS |
|
Phase 1/2 Results |
Oncology |
None |
|